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Abstract
Background/Aims: A recent decrease in patient survival has been reported among
hepatitis C virus (HCV)-infected liver transplant recipients and this may be
attributable to progression of ﬁbrosis. We reported previously that cyclosporine
suppressed the proliferation of, and collagen production in, hepatic stellate cells
(HSCs). Here, we investigated the effects of NIM811, a cyclosporine analogue, on
cell growth, collagen production and collagenase activity in HSCs. Methods: Rat
HSCs and human HSC-derived TWNT-4 cells were cultured for the study. The
expression of collagen, matrix metalloproteinase 1 (MMP-1) and tissue inhibitor
of metalloproteinase-1 (TIMP-1) and collagenase activity was evaluated. Cell
proliferation and apoptosis were measured. Phosphorylation of mitogen-activated
protein kinases (MAPKs), Smad2 and Smad3 was evaluated. The expression of the
tumour growth factor-b (TGF-b)-receptor and Smad7 genes was also evaluated.
Results: NIM811, as well as cyclosporine, suppressed the transcription and
synthesis of collagen and stimulated the production of MMP-1 with a concomitant
enhancement of collagenase activity, although it did not change the expression of
TIMP-1. NIM811 inhibited proliferation without induction of apoptosis. In the
MAPKs and TGF-b signalling pathways, NIM811 enhanced the phosphorylation
of JNK and p38, but not extracellular signal-regulated kinases 1 and 2, and
suppressed the phosphorylation of Smad2 and Smad3, accompanied by increased
Smad7 transcription and decreased TGF-b-receptor transcription. Conclu-
sion: These ﬁndings demonstrate that NIM811 not only suppresses collagen
production and proliferation but also increases collagenase activity. These effects
are accompanied by inhibition of TGF-b signalling pathways.
In liver transplantation, a signiﬁcant decline in patient
survival, caused by rapid progression to decompen-
sated graft cirrhosis, is an important clinical issue
for hepatitis C virus (HCV)-positive patients, whereas
there has been an improvement in the survival of
HCV-negative patients (1–5). Progression to cirrhosis
has been estimated to occurin up to 30% of patients at
5 years after transplantation, and the rate of disease
progression has been greater in patients who under-
went transplantation in recent years compared with
those who underwent transplantation a longer period
of time ago (1, 2, 4). Several variables, including donor
age, degree of immunosuppression and viral load, are
implicated in the recent increase in progression (2, 3).
Indeed, Berenguer et al. (3, 5) reported that HCV-
infected patients who received immunosuppressive
therapy with cyclosporine were less likely to develop
graft cirrhosis than those who received tacrolimus,
indicating that the choice of calcineurin inhibitor may
inﬂuence disease progression (6).
Hepatic stellate cells (HSCs) are nonparenchymal
livercells that have a characteristic stellate morphology
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Following liver injury, HSCs undergo transdifferentia-
tion to an activated myoﬁbroblastic phenotype and
express a-smooth muscle actin. Activated HSCs then
proliferate and produce extracellular matrices (ECM)
such as collagens (7, 8). Previously, we evaluated
the effects of immunosuppressive drugs, such as cyclos-
porine and tacrolinus, on HSCs. Cell proliferation and
collagen production were suppressed by cyclosporine
but not by tacrolimus, indicating that cyclosporine
potentially has an anti-ﬁbrogenic effect (9).
Cyclosporine is an immunosuppressive cyclic undeca-
peptide, and binds with nanomolar afﬁnity to cyclophi-
lins. The complex of cyclosporine and cyclophilin A
inhibits calcineurin, a calcium-dependent phosphatase
that regulates the expression of various cytokine genes in
activated T-lymphocytes (10–12). NIM811 is a
four-substituted cyclosporine that does not bind to
cyclophilin A and therefore lacks immunosuppressive
activity; however, it retains the ability to bind other
cyclophilins, such as cyclophilin B (13). Recently,
NIM811, as well as cyclosporine, showed a suppressive
effect on HCVat the RNA and protein levels in an HCV
subgenomic replicon cell culture system (14). In this
study, we investigated the effects of NIM811 on prolifera-
t i o n ,c o l l a g e np r o d u c t i o na nd collagenase activity in
HSCs in vitro. We demonstrated that NIM811 not only
suppressed proliferationand collagenproductionbutalso
enhanced collagenase activity in HSCs, indicating that
NIM811 is a potential candidate for anti-ﬁbrosis therapy.
Materials and methods
Cell culture
Hepatic stellate cells were isolated from the liver of male
Wistar rats by sequential in situ perfusionwith collagenase
and digestion with pronase, followed by centrifugation in
a double-layered (17%/11.5%) metrizamide solution
(Sigma Chemical, St Louis, MO, USA), as described
previously (15). HSCs were cultured in Dulbecco’s mod-
iﬁedEagle’s medium(DMEM)with10% foetalcalfserum
(FCS). The experiments described in this study were
performed on cells between the third and fourth serial
passages. Because commercialk i t sf o rt h em e a s u r e m e n to f
mouse or rat matrix metalloproteinase 1 (MMP-1) and
tissue inhibitor of metalloproteinase-1 (TIMP-1) were
not available, we used TWNT-4 cells, a human cell line
derived from HSCs (16), to evaluate the effects of NIM811
on MMP-1 and TIMP-1. TWNT-4 cells were cultured in
DMEM with 10% FCS as reported previously (16).
NIM811 was donated by Novartis Pharma AG (Basel,
Switzerland). NIM811 was dissolved in DMEM and
added to the cultures. The cell viability of HSCs was
more than 90% under serum-free conditions for 24h
in the presence of 2mM NIM811 under serum-free
conditions.
Type I collagen assay
Cultured HSCs were incubated in a serum-free medium
in the presence or absence of NIM811 for 24h. Type I
collagen was determined in culture media by ELISA as
described previously (17). Anti-rat type I collagen anti-
body (LSL, Tokyo, Japan) was used as the primary
antibody and peroxidase-conjugated goat-anti-rabbit
IgG (Organon Teknika Corporation, Durham, NC,
USA) was used as the secondary antibody. Rat tail
tendon collagen type I (Advance Biofactures Corpora-
tion, Lymbrook, NY, USA) was used as the standard.
Matrix metalloproteinase 1, tissue inhibitor of
metalloproteinase-1 and collagenase assay
Cultured TWNT-4 cells were incubated in a serum-
free medium in the presence or absence of NIM811 for
24h. MMP-1 and TIMP-1 productions were deter-
mined in culture media by ELISA using a Biotrak
ELISA system for human MMP-1 (Amersham Bios-
ciences, Piscataway, NJ, USA) and an hTIMP-1 kit
(Daiichi Fine Chemical Co. Ltd, Toyama, Japan)
respectively (18). Active MMP-1 and pro-MMP-1 in
culture media were determined using an MMP-1
Biotrak Activity Assay System (Amersham) (18).
Analysis of gene expression using real-time reverse
transcriptase-polymerase chain recation
Total RNA was prepared with Trizol reagent (Invitro-
gen, Carlsbad, CA, USA) from TWNT-4 cells that were
maintained in either the presence or absence of
NIM811 in 10% FCS for 24h. cDNA was synthesized
from 1.0mg RNA with GeneAmp
TM RNA PCR (Ap-
plied Biosystems, Branchburg, NJ, USA) using random
hexamers. Real-time PCR was performed using Light-
Cycler-FastStart DNA Master SYBR Green 1 (Roche,
Tokyo, Japan) as described previously (19). The reac-
tion mixture (20mL) contained LightCycler-FastStart
DNA Master SYBR Green 1, 4mM MgCl2,0 . 5mMo f
the upstream and downstream PCR primers and 2mL
of the ﬁrst-strand cDNA as a template. To control for
variations in the reactions, all PCRs were normalized
against glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) expression. The primers used were as fol-
lows: 50-AGGGTGAGACAGGCGAACAG-30 (forward
primer) and 50-CTCTTGAGGTGGCTGGGGCA-30
(reverse primer) for human type I collagen a1 chain
(GenBank
TM accession number NM000088) (20);
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mer) and 50-TCCGGGTAGAAGGGATTTGTG-30 (re-
verse primer) for MMP-1 (GenBank
TM accession
number NM002421) (21); 50-TTCTGCAATTCCG
ACCTCGT-30 (forward primer) and 50-TCCGTCCAC
AAGCAATGAGT-30 (reverse primer) for TIMP-1 (Ref.
3; GenBank
TM accession number NM003254) (22); 50-
GGATCTCAGGCATTCCTCGG-30 (forward primer)
and 50-CAGTATGCCACCACGCACCA-30 (reverse pri-
mer) for Smad7 (23); and 50-GGCCGTTTGTATGTG
CACCCTC-30 (forward primer) and 50-GGGCGAT
CTAATGAAGGGTCC-30 (reverse primer) for TGF-b-
receptor I (TGF-b-RI) (24).
Analysis of bromodeoxyuridine incorporation
Hepatic stellate cell incorporation of bromodeoxyur-
idine (BrdU) was measured using a cell proliferation
ELISA (Roche Diagnostics GmbH, Mannheim, Ger-
many) as described previously (25). Brieﬂy, subcon-
ﬂuent HSCs were serum starved for 24h. They were
then washed with DMEM and incubated for 24h with
BrdU in DMEM with 10% FCS in the presence or
absence of NIM811. After labelling the cells with BrdU,
cellular DNA was digested and incubated with the
anti-BrdU antibody conjugated with peroxidase. BrdU
incorporation was estimated by measuring the ﬂuor-
escence intensity of the supernatant at 450nm (excita-
tion) and 690nm (emission).
Analysis of apoptosis
Hepatic stellate cells were maintained in either the
presence or absence of NIM811 under serum-free
conditions for 24h. Cells were ﬁxed for 30min in 4%
paraformaldehyde/PBS at room temperature, and per-
meabilized for 5min in PBS containing 0.2% Triton X-
100 at 41C. Cells were then stained with Hoechst
33342 and analysed by the terminal deoxynucleotidyl
Transferase Biotin-dUTP nick end labeling method
using an in situ Cell Death Detection Kit (Roche)
according to the manufacturer’s instructions.
The samples were visualized with an LSM 510 con-
focal laser scanning microscope (Carl Zeiss, Jena,
Germany). At least 100 cells from three independent
experiments and from three different cell preparations
were counted for each condition.
Western blot analysis for phospho- and
nonphospho-mitogen-activated protein kinases
Western blot analysis was basically performed essen-
tially as described previously (26). After starving HSCs
for 24h, they were treated with or without NIM811 for
2h or mock treated. Whole-cell lysates containing
1 10
7 TWNT-4 cells were prepared in 100mL so-
dium dodecyl sulphate-polyacrylamide gel electro-
phoresis sample buffer. Protein lysates were subjected
to 12% SDS-PAGE, transferred to a polyvinylidene
diﬂuoride membrane (Millipore, Bedford, MA, USA)
and probed with the primary antibodies for extra-
cellular signal-regulated kinases 1 and 2 (ERK1/2)
mitogen-activated protein kinase (MAPK), phospho-
ERK1/2 MAPK (Thr202/Tyr204), Jun N-terminal
kinase (JNK), phospho-JNK (Thr183/Tyr185), p38
MAPK or phospho-p38 MAPK (Thr180/Tyr182)
(New England Biolabs, Beverly, MA, USA). Antibody
binding was detected using peroxidase-linked anti-
rabbit IgG (Amersham Pharmacia Biotech, Piscataway,
NJ, USA) as the secondary antibody. The blots were
developed using ECL-plus (Amersham Pharmacia Bio-
tech) to visualize the antibodies. The levels of ERK1/2
MAPK, phosphorylated-ERK1/2 MAPK, JNK, phos-
phorylated-JNK, p38 MAPK and phosphorylated-p38
MAPK were quantiﬁed by densitometry using an
optical scanner system. For comparison, the ratios of
phosphorylated ERK1/2, JNK and p38 MAPK to non-
phosphorylated ERK1/2, JNK and p38 MAPK, respec-
tively, were calculated from the densitometric data.
Western blot analysis for phospho- and
nonphospho-Smad2 and Smad3
Western blot analysis was performed as described
above, probed with the primary antibody for Smad2,
phospho-Smad2 (Thr/Tyr), Smad3 or phospho-
Smad3 (Thr/Tyr) (Cell Signaling Technology, Danvers,
MA, USA). For comparison, the ratios of phosphory-
lated Smad2 and Smad3 to nonphosphorylated Smad2
and Smad3, respectively, were calculated from the
densitometric data.
Statistical analysis
All results are shown as the mean SEM. Compar-
isons were made using one-way ANOVA, followed by
Scheffe’s test or the Mann–Whitney test.
Results
Effects of NIM811 on type I collagen accumulation,
matrix metalloproteinase 1 and tissue inhibitor of
metalloproteinase-1 production and collagenase
activity
To assess the effect of NIM811 on ECM production by
HSCs, we determined type Icollagen concentrations in
culture media after adjusting the number of rat HSCs.
Treatment of the cells with increasing concentrations
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tion-dependent suppression of collagen accumulation;
0.5mM NIM811 reduced collagen accumulation by
approximately 50% (Fig. 1). As reported previously (9),
cyclopsorine at the clinically relevant concentration of
0.125mM (150ng/mL) reduced collagen production by
approximately 50%, whereas tacrolimus at the clinically
relevant concentration of 12.5nM (10ng/mL) did not
reduce collagen production signiﬁcantly (Fig. 1).
Because collagenase activity affects accumulation of
type I collagen, we evaluated the effects of NIM811 on
collagenase activity in TWNT-4 cells. NIM811 led to a
concentration-dependent increase in collagenase ac-
tivity (active MMP-1); in the presence of 0.5mM
NIM811, collagenase activity increased roughly two-
fold (Fig. 2A). Because collagenase activity is regulated
by the balance between MMP-1 and TIMP-1, we also
evaluated TIMP-1 production in TWNT-4 cells.
NIM811 tended to reduce TIMP-1 production in a
concentration-dependent manner; however, NIM811
did not reduce TIMP-1 production signiﬁcantly, even
at a concentration of 2.0mM (Fig. 2B).
Effects of NIM811 on gene expression of type I
collagen, matrix metalloproteinase 1 and tissue
inhibitor of metalloproteinase-1
We used RT-PCR to evaluate the effects of NIM811 or
cyclosporine on the mRNA levels of type I collagen,
MMP-1 and TIMP-1. The expression of type I collagen
was reduced by roughly 30% in the presence of
0.5mM NIM811 (Fig. 3A). In contrast, 0.5mM
NIM811 increased the expression of MMP-1 nearly
two-fold (Fig. 3B) but did not affect that of TIMP-1
(Fig. 3C). These results indicated that the effects of
NIM811 on gene expression were similar to its effect
on protein production.
Effect of NIM811 on cell proliferation and apoptosis
Bromodeoxyuridine incorporation was measured to
investigate the effect of NIM811 on cell proliferation.
Quantitative analysis showed that 2.0mM NIM811
treatment decreased new DNA synthesis by nearly
30%, although treatment with lower concentrations
had a reduced effect (Fig. 4). Next, we evaluated the
effects of NIM811 on apoptosis; even in the presence
of 2mM NIM811, little apoptosis was observed (data
not shown).
Fig. 1. Effects of NIM811, cyclosporine (CsA) and tacrolimus
(Tc) on the accumulation of type I collagen in rat hepatic stellate
cells (HSCs). NIM811, as well as cyclosporine, caused a
concentration-dependent inhibition of type I collagen
production. In contrast, tacrolimus did not show these
suppressive effects at a clinically relevant concentration
(i.e. 12.5nM, equivalent to 10ng/mL). The data represent
mean SEM from ﬁve independent experiments. and
Statistically signiﬁcant differences (Po0.05 and o0.01
respectively) compared with HSCs in the absence of NIM811,
CsA and Tc.
Fig. 2. Effects of NIM811 on matrix metalloproteinase 1 (MMP-1) activity (collagenase activity) and tissue inhibitor of
metalloproteinase-1 (TIMP-1) production in TWNT-4 cells. NIM811 caused a concentration-dependent enhancement of MMP-1
activity (collagenase activity) (A). NIM811 also tended to reduce TIMP-1 production in a concentration-dependent manner (B). The
data represent mean SEM from ﬁve independent experiments. and Statistically signiﬁcant differences (Po0.05 and o0.01
respectively) compared with hepatic stellate cells (HSCs) in the absence of NIM811.
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Because cell growth and the expression of genes
involved in the process of cell growth are widely
regulated through MAPK signal cascades, we assessed
the effects of NIM811 on MAPK activity, including
ERK1/2, JNK and p38. Treatment with NIM811 sig-
niﬁcantly enhanced the phosphorylation of JNK and
p38 MAPK in a concentration-dependent manner, but
did not enhance the phosphorylation of ERK1/2 (Fig.
5A–C). NIM811 at a concentration of 0.5mM en-
hanced the phosphorylation of JNKand p38 MAPK by
nearly 3.6- and 2.3-fold respectively (Fig. 5B and C).
Effects of NIM811 on tumour growth factor-b
signalling pathways
Because TGF-b signal cascades through Smad2 and
Smad3 strongly regulate the expression of the type I
collagen gene (27), we evaluated the effects of NIM811
on the phosphorylation of Smad2 and Smad3.
Treatment with NIM811 signiﬁcantly suppressed the
phosphorylation of Smad2 and Smad3 in a concentra-
tion-dependent manner; 0.5mM NIM811 suppressed
thephosphorylation ofSmad2 andSmad3 by nearly 70
and 60% respectively (Fig. 6A and B). Next, we
evaluated the expression of Smad7, which negatively
regulates TGF-b signalling pathways by inhibition of
TGF-b-RI phosphorylation (28). 0.5mM NIM811
Fig. 3. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of type I collagen, matrix metalloproteinase 1
(MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) mRNA expression. Total RNA was extracted from hepatic stellate cells
(HSCs) treated with NIM811 (0.5, 1 or 2mM) or mock treated. Samples were analysed by real-time RT-PCR and all PCR reactions were
normalized for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. NIM811 reduced the expression of type I collagen
(A) and TIMP-1 (C) but it enhanced the expression of MMP-1 (B). The ratio of expression in the absence of NIM811 was used as a
control (100%). The data represent mean SEM from three independent experiments. and Statistically signiﬁcant differences
(Po0.05 and Po0.01 respectively) compared with HSCs in the absence of NIM811.
Fig. 4. Effects of NIM811 on BrdU incorporation into hepatic
stellate cells (HSCs). NIM811 (2.0mM) decreased BrdU
incorporation in cells by nearly 30% compared with untreated
cells, although treatment with a lower concentration did not.
The data represent mean SEM from ﬁve independent
experiments. Statistically signiﬁcant difference (Po0.05)
compared with HSCs in the absence of NIM811.
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(Fig. 7A) and it suppressed that of TGF-b-RI by nearly
50% (Fig. 7B).
Discussion
A recent study by Berenguer et al. (3) demonstrated
that HCV-infected patients receiving immunosuppres-
sive therapy with cyclosporine were less likely to
develop graft cirrhosis than those treated with tacroli-
mus. We reported previously that cyclosporine at the
clinically relevant concentration of 0.125mM (150ng/
mL) signiﬁcantly reduced collagen production in
HSCs, while tacrolimus at the clinical concentration of
12.5nM (10ng/mL) did not (9). In this study, we
demonstrated that NIM811 (0.125mM), as well as
cyclosporine, produced a concentration-dependent
suppression of collagen accumulation (Fig. 1). We also
found that this suppression was regulated at least as far
upstream as the transcriptional level because treatment
with NIM811 suppressed collagen gene expression.
Collagen accumulation, in addition to being deter-
mined by the rate of collagen production, is also
regulated by collagenase activity, speciﬁcally, by the
balance between MMP-1 and TIMP-1. We found that
treatment of the cells with NIM811 increased collage-
nase activity, accompanied by stimulation of the tran-
scription and synthesis of MMP-1 and weak
suppressionoftheexpressionofTIMP-1(Figs2and3).
Fig. 5. Western blot analysis of phosphorylated and nonphosphorylated extracellular signal-regulated kinases 1 and 2 (ERK1/2) (A),
JNK (B) and p38 (C). NIM811 enhanced the phosphorylation of JNK and p38, but not ERK1/2. Each ﬁgure is representative of three
independent experiments. Band intensities were measured to determine the ratios of phosphorylated to nonphosphorylated ERK1/2,
JNK and p38. The ratio of phosphorylation in the absence of NIM811 was used as a control (100%). The values shown are the
mean SEM oftriplicate determination.andStatistically signiﬁcant differences (Po0.05 and o0.01 respectively) comparedwith
hepatic stellate cells (HSCs) in the absence of NIM811.
Fig. 6. Western blot analysis of phosphorylated and
nonphosphorylated Smad2 and Smad3. NIM811 strongly
suppressed the phosphorylation of Smad2 (A) and Smad3 (B).
Each ﬁgure is representative of three independent experiments.
Band intensities were measured to determine the ratios of
phosphorylated to nonphosphorylated Smad2 and Smad3. The
ratio of phosphorylation in the absence of NIM811 was used as
a control (100%). The values shown are the mean SEM of
triplicate determination. and Statistically signiﬁcant
differences (Po0.05 and o0.01 respectively) compared with
hepatic stellate cells (HSCs) in the absence of NIM811.
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to stimulating collagen production, activated HSCs
inhibit the degradation of interstitial collagens by
collagenases such as MMP-1, indicating that matrix
degradation is inhibited during the progression of
ﬁbrosis (29–31). TIMP-1 has been reported to regulate
cell growth and apoptosis independent of the inhibi-
tionof matrixdegradation (32).We demonstratedthat
NIM811 suppressed the growth of HSCs in a concen-
tration-dependent manner without apoptosis (Fig. 4).
Taken together, these results indicate that NIM811 has
therapeutic potential for liver ﬁbrosis through sup-
pression of collagen production and enhancement of
collagenase activity.
To explore the mechanism by which NIM811 sup-
presses collagen production and cell proliferation, and
enhances collagenase activity, we examined the effects of
NIM811 on intra-cellular signalling cascades, such as
MAPK cascades, which play important roles in collagen
production and cell proliferation in HSCs (33). It is
intriguing that NIM811 enhanced the activation of JNK
and p38 but not ERK1/2 (Fig. 5). In contrast, cyclospor-
ine suppressed the activation of JNK and p38, as we
reported previously (9). It was shown that cyclosporine
exerts its immunosuppressive effects through both the
calcineurin-dependent nuclear factor of activated T cells
(NFAT) pathway and the calcineurin-independent acti-
vation pathway for JNK and p38 (34). NIM811, an
analogue of cyclosporine, does not activate the NFAT
pathway because it cannot bind to cyclophilin A (13).
The different effects of NIM811 and cyclosporine on
JNK and p38 might be attributable to the absence of an
effect of NIM811 on the NFAT pathway.
In addition to MAPKs, TGF-b signalling cascades
strongly stimulate collagen production by HSCs (28).
TGF-b binds to TGF-b-RII on the cell membrane, and
then TGF-b-RII phosphorylates TGF-b-RI at the ser-
ine and threonine residues located in its glycine-/
serine-rich domain (35). The phosphorylated TGF-b-
RI phosphorylates Smad2 and Smad3 at a C-terminal
SSXS motif and these form a complex with their
common partner Smad4. These Smad proteins trans-
locate to the nucleus and activate the transcription of
target genes such as collagen (35). In this study, we
demonstrated that Smad2 and Smad3 were constitu-
tively phosphorylated in activated HSCs, as reported
previously (36), and that NIM811 suppressed the
phosphorylation of Smad2 and Smad3 (Fig. 6). These
results suggest that NIM811 may inhibit the kinase
activity of TGF-b-RII and/or TGF-b-RI. Several mole-
cules such as Smad7 (28, 37), immunophilin FK506-
binding protein (FKBP) 12 (38) and Smad anchor for
receptor activation (SARA) (39) are associated with
TGF-b-R and regulate TGF-b signalling. We found
that NIM811 enhanced the expression of Smad7, and
suppressed that of TGF-b-RI, indicating that NIM811
inhibits the TGF-b signalling pathways, at least par-
tially through blockade at the receptor level. We also
found that cyclosporine had similar effects on Smad2,
Smad3, Smad7 and TGF-b-RI (unpublished data). As
mentioned above, NIM811 had effects opposite to
those of cyclosporine on JNK and p38, although both
showed similar effects on collagen production and cell
proliferation, suggesting that NIM811 and cyclospor-
ine exhibit antiﬁbrogenic effects mainly by blockade of
TGF-b signalling pathways.
Because NIM811 lacks the ability to bind to cyclo-
philin A (13), NIM811 exerts its pharmacological
effects by binding to other cyclophilins, such as
cyclophilin B or D. Cyclophilins are a family of PPIases
that catalyse the cis-trans interconversion of peptide-
bound amino-terminal proline residues, facilitating
Fig. 7. Real-time reverse transciptase-polymerase chain reaction (RT-PCR) analysis of Smad7 and tumour growth factor-b (TGF-b)-RI
mRNA expression. Total RNA was extracted from hepatic stellate cells (HSCs) treated with NIM811 (0.5, 1, or 2mM) or mock treated.
Samples were analysed by real-time RT-PCR, and all PCR reactions were normalized for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) expression. NIM811 enhanced the expression of Smad7 (A), and it reduced the expression of TGF-b-RI (B). The ratio of
expression in the absence of NIM811 was used as a control (100%). The data represent mean SEM from three independent
experiments. Statistically signiﬁcant differences (Po0.01) compared with HSCs in the absence of NIM811.
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than 10 subtypes of cyclophilin and they are involved
in numerous cellular processes, including transcrip-
tional regulation, immune response, protein secretion
and mitochondrial function (40, 41). Watashi et al.
(42) recently reported that NIM811 suppressed the
replication of an HCV replicon in vitro, whereas
tacrolimus did not show this effect. Notably, NIM811
exerts its antiviral effects via binding cyclophilin B,
which is a functional regulator of HCV RNA polymer-
ase (43). NIM811 has also been reported to have
cytoprotective properties depending on interference
with the interaction with cyclophilin D, which regu-
lates the mitochondrial permeability transition (13).
Kon et al. (44) reported that NIM811 prevented
acetaminophen-induced necrosis and apoptosis of
cultured mouse hepatocytes. In order to explain the
detailed working mechanism of NIM811, cyclophilins
interacting with NIM811 are important factors; how-
ever, we have not determined which cyclophilin is
utilized by NIM811 to exert its anti-ﬁbrogenic and
anti-proliferating activity. We arenow in the processof
identifying the target cyclophilin.
In conclusion, we demonstrated that NIM811, as well
as cyclosporine, had anti-ﬁbrogenic effects. NIM811 has
no immunosuppressive activity and, in consideration of
the toxicity data, seems more favourable for clinical use
because of the absence of signiﬁcant changes in kidney-
speciﬁc parameters following 10 days of 50mg/kg of oral
NIM811, whereas the same dose regimen of cyclospor-
ine produced signs of renal dysfunction (45). NIM811
would be a plausible candidate for prevention of the
progression of HCV-related graft-cirrhosis after liver
transplantation because of its anti-viral and anti-ﬁbro-
genic effects in vitro. Further studies in vivo will be
required to determine whether NIM811 is effective for
the treatment of hepatic ﬁbrosis.
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